Patents by Inventor Xiaoteng LV

Xiaoteng LV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof
    Publication number: 20230053305
    Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
    Type: Application
    Filed: September 23, 2022
    Publication date: February 16, 2023
    Inventors: Yutian WEI, Lin ZHU, Yanfeng LI, Yihong YAO, Xin YAO, Jiaqi HUANG, Li ZHANG, Shigui ZHU, Xiaoteng LV
  • BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
    Patent number: 11498973
    Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: November 15, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yutian Wei, Lin Zhu, Yanfeng Li, Yihong Yao, Xin Yao, Jiaqi Huang, Li Zhang, Shigui Zhu, Xiaoteng Lv
  • BCMA-Targeted Chimeric Antigen Receptor as well as Preparation Method Therefor and Application Thereof
    Publication number: 20210403590
    Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
    Type: Application
    Filed: September 16, 2021
    Publication date: December 30, 2021
    Inventors: Yutian WEI, Lin ZHU, Yanfeng LI, Yihong YAO, Xin YAO, Jiaqi HUANG, Li ZHANG, Shigui ZHU, Xiaoteng LV
  • BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
    Patent number: 11142581
    Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: October 12, 2021
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yutian Wei, Lin Zhu, Yanfeng Li, Yihong Yao, Xin Yao, Jiaqi Huang, Li Zhang, Shigui Zhu, Xiaoteng Lv
  • BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    Publication number: 20200362048
    Abstract: The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.
    Type: Application
    Filed: May 22, 2020
    Publication date: November 19, 2020
    Applicant: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yutian WEI, Lin ZHU, Yanfeng LI, Yihong YAO, Xin YAO, Jiaqi HUANG, Li ZHANG, Shigui ZHU, Xiaoteng LV